Skip to main content
OpenTrials
Completed

NCT Number: NCT05803096

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

Transrectal prostate biopsy is a commonly performed ambulatory procedure for diagnosing prostate cancer. Prostate biopsy are associated with pain or anxiety. Nitrous oxide (or laughing gas) is a well-known inhaled anesthetic which is frequently used in dental offices and for pediatric procedures to alleviate a patient's anxiety and pain. This study seeks to determine whether administration of nitrous oxide at the time of prostate biopsy will improve a patient's experience of care.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Nitrous oxide is a well-tolerated inhaled anesthetic that has been used for decades in pediatric and adult populations and is largely viewed as effective and safe. In addition to analgesic effect, nitrous oxide also produces a dissociative euphoria and amnesia that could potentially improve patients' anxiety and experience of cancer care. When used as a single agent at concentrations ≤50%, the American Society of Anesthesiologists (ASA) classifies nitrous oxide as Minimal Sedation, producing a state in which a patient responds normally to verbal commands, maintains airway reflexes, and spontaneous ventilation. Over the past several decades nitrous oxide has become less common due to concerns of nitrous oxide environmental exposure to the care team. There are now Federal Drug Administration (FDA)-approved systems that allow patient self-administered nitrous oxide (SANO), and importantly, include a scavenger system to eliminate exhaled environmental nitrous oxide. These systems are rapidly being adopted throughout the United States in Urology practices, but to date, there have been no studies evaluating patient outcomes and possible risks with the adjunct use of SANO. This study is a prospective, randomized, controlled trial to assess patient perceived pain and anxiety related to prostate needle biopsy with or without SANO, and the frequency of complications associated with SANO. A secondary aim will be to demonstrate that the SANO at the time of prostate biopsy does not significantly increase burden on Urologist productivity, nor increase the difficulty of operator ease in performing the prostate needle biopsy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Biological male
  • Aged 18 to 85 years
  • Scheduled for clinically-indicated prostate needle biopsy
  • Suitable for nitrous oxide/oxygen with willingness to be randomized to inhaled SANO or inhaled oxygen during the procedure
  • Access to an email and computer

Exclusion criteria

  • Perioral facial hair impeding good mask seal
  • Learning disabilities and/or inability to cognitively complete survey questions
  • Taken a pre-procedure benzodiazepine or narcotic.
  • Has any of the following medical conditions:
  • Inner ear, bariatric or eye surgery within the last 2 weeks,
  • Current emphysematous blebs,
  • Severe B-12 deficiency.
  • Bleomycin chemotherapy within the past year.
  • Class III or higher heart failure.
  • Undergoing novel therapy for prostate cancer

Treatment and study plan

Self-Administered Nitrous Oxide

Drug

Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.

Other names: nitrous oxide

Oxygen

Other

Oxygen will be administered at 10 Liters/min for the duration of prostate biopsy.

Primary outcomes

  1. Post-biopsy Pain (VAS-P)

    Time frame: 5-minutes after prostate biopsy

    Pain experienced immediately following prostate biopsy as measured by a Visual Analog Scale for Pain (VAS-P) (range: 0 [no pain] - 10 [worst pain])

  2. Post-biopsy Anxiety (VAS-A)

    Time frame: 5-minutes after prostate biopsy

    Anxiety experienced immediately following prostate biopsy as measured by a Visual Analog Scale for Anxiety (VAS-A) (range: 0 [no anxiety] - 10 [worst anxiety])

  3. Post-biopsy Anxiety Traits (STAI)

    Time frame: 5-minutes after prostate biopsy

    Anxious traits exhibited after prostate biopsy as measured by the State Trait Anxiety Inventory (STAI) (range: 6-36; 36 being 'worst' anxiety).

Secondary outcomes

  1. Time of Prostate Biopsy

    Time frame: Length of prostate biopsy; up to 30 minutes

    Length of procedure will be compared between arms to assess whether SANO significantly lengthens prostate biopsy

  2. Operator Assessment of "Tolerating Insertion of Rectal Probe"

    Time frame: Immediately after prostate biopsy; within 5 minutes after completion of biopsy.

    Operating urologist filled out a survey to assess their perception of patient: Tolerating Insertion of rectal probe. Responses were scored on a 3-point Likert scale as 1 (worse than expected), 2 (as expected), or 3 (better than expected).

  3. Operator Assessment of "Patient Maintenance of Positioning"

    Time frame: Immediately after prostate biopsy; within 5 minutes after completion of biopsy.

    Operating urologist filled out a survey to assess their perception of patient: Patient maintenance of positioning. Responses were scored on a 3-point Likert scale as 1 (worse than expected), 2 (as expected), or 3 (better than expected).

  4. Operator Assessment of "Patient Tolerance of Procedure"

    Time frame: Immediately after prostate biopsy; within 5 minutes after completion of biopsy.

    Operating urologist filled out a survey to assess their perception of patient: Patient Tolerance of Procedure. Responses were scored on a 3-point Likert scale as 1 (worse than expected), 2 (as expected), or 3 (better than expected).

Sponsors and collaborators

Lead sponsor

Beth Israel Deaconess Medical Center

Other

Collaborators

  • Brigham and Women's Hospital

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 7, 2023
Registry last updated
Jan 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.